Literature DB >> 20653676

CYP4F2 rs2108622: a minor significant genetic factor of warfarin dose in Han Chinese patients with mechanical heart valve replacement.

Han-Jing Cen1, Wu-Tao Zeng, Xiu-Yu Leng, Min Huang, Xiao Chen, Jia-Li Li, Zhi-Ying Huang, Hui-Chang Bi, Xue-Ding Wang, Yan-Ling He, Fan He, Rui-Na Zhou, Qi-Shan Zheng, Li-Zi Zhao.   

Abstract

WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT * Genetic polymorphisms of VKORC1 and CYP2C9 are known to influence warfarin dosage. * Recent studies among Caucasians showed that polymorphisms of CYP4F2 also play a role in warfarin pharmacogenetics. * The contribution of CYP4F2 variants to the variability inwarfarin dose requirement in Chinese subjects remains to be investigated. WHAT THIS STUDY ADDS * This research was to study the effect of CYP4F2 variants on warfarin requirements in the Han Chinese population. * This study developed a multiple regression model including CYP2C9, VKORC1 3673G>A, CYP4F2 genotypes and age, weight, combination use of amiodarone which could explain 56.1% of the individual variability in warfarin dose CYP4F2 could explain 4% of the variance in warfarin dose. * We found that one novel genotypic polymorphism 5417G>T for Asp36Tyr, which was identified as an important marker of warfarin resistance, was absent in the Han Chinese population in our study. AIMS The objective of this study was to assess the effect of the CYP4F2 on the daily stable warfarin dose requirement in Han Chinese patients with mechanical heart valve replacement (MHVR). METHODS From March 2007 to November 2008, 222 Han Chinese MHVR patients were recruited in our study. VKORC1 3673G>A, 5417G>T, CYP2C9*3 and CYP4F2 rs2108622 were genotyped by using the polymerase chain reaction restriction fragment length polymorphism method (PCR-RFLP). Polymorphisms of VKORC1 9041G>A were detected by direct sequencing. Multiple linear regression analysis was used to investigate the contribution of CYP4F2. RESULTS The CYP4F2 rs2108622 CT/TT group took a significantly higher stable warfarin dose (3.2 mg day(-1)) than the CC group (2.9 mg day(-1), 95% CI 0.2, 1.0, P= 0.033). The multiple linear regression model included VKORC1 3673G>A, CYP2C9, CYP4F2 genotypes and clinical characteristics. The model could explain 56.1% of the variance in stable warfarin dose in Han Chinese patients with MHVR. CYP4F2 contributed about 4% to the variance in the warfarin dose. There was no variation in the SNPs of VKORC1 5417G>T. CONCLUSION CYP4F2 is a minor significant factor of individual variability in the stable warfarin dose in Han Chinese patients with MHVR. The effect of CYP2C9 and VKORC1 genotypes on variability in the stable warfarin dose had also been confirmed.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20653676      PMCID: PMC2911553          DOI: 10.1111/j.1365-2125.2010.03698.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  29 in total

1.  The International HapMap Project.

Authors: 
Journal:  Nature       Date:  2003-12-18       Impact factor: 49.962

2.  A general method for isolation of high molecular weight DNA from eukaryotes.

Authors:  N Blin; D W Stafford
Journal:  Nucleic Acids Res       Date:  1976-09       Impact factor: 16.971

3.  The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism.

Authors:  T H Sullivan-Klose; B I Ghanayem; D A Bell; Z Y Zhang; L S Kaminsky; G M Shenfield; J O Miners; D J Birkett; J A Goldstein
Journal:  Pharmacogenetics       Date:  1996-08

4.  A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity.

Authors:  Hsiang-Yu Yuan; Jin-Jer Chen; M T Michael Lee; Ju-Chieh Wung; Ying-Fu Chen; Min-Ji Charng; Ming-Jen Lu; Chi-Ren Hung; Chun-Yu Wei; Chien-Hsiun Chen; Jer-Yuarn Wu; Yuan-Tsong Chen
Journal:  Hum Mol Genet       Date:  2005-05-11       Impact factor: 6.150

5.  A prospective, randomized pilot trial of model-based warfarin dose initiation using CYP2C9 genotype and clinical data.

Authors:  Michael A Hillman; Russell A Wilke; Steven H Yale; Humberto J Vidaillet; Michael D Caldwell; Ingrid Glurich; Richard L Berg; John Schmelzer; James K Burmester
Journal:  Clin Med Res       Date:  2005-08

Review 6.  Systematic overview of warfarin and its drug and food interactions.

Authors:  Anne M Holbrook; Jennifer A Pereira; Renee Labiris; Heather McDonald; James D Douketis; Mark Crowther; Philip S Wells
Journal:  Arch Intern Med       Date:  2005-05-23

7.  CYP4F2 is a vitamin K1 oxidase: An explanation for altered warfarin dose in carriers of the V433M variant.

Authors:  Matthew G McDonald; Mark J Rieder; Mariko Nakano; Clara K Hsia; Allan E Rettie
Journal:  Mol Pharmacol       Date:  2009-03-18       Impact factor: 4.436

8.  Metabolism of arachidonic acid to 20-hydroxy-5,8,11, 14-eicosatetraenoic acid by P450 enzymes in human liver: involvement of CYP4F2 and CYP4A11.

Authors:  P K Powell; I Wolf; R Jin; J M Lasker
Journal:  J Pharmacol Exp Ther       Date:  1998-06       Impact factor: 4.030

9.  Relative impact of covariates in prescribing warfarin according to CYP2C9 genotype.

Authors:  Michael A Hillman; Russell A Wilke; Michael D Caldwell; Richard L Berg; Ingrid Glurich; James K Burmester
Journal:  Pharmacogenetics       Date:  2004-08

10.  Validation of methods for CYP2C9 genotyping: frequencies of mutant alleles in a Swedish population.

Authors:  U Yasar; E Eliasson; M L Dahl; I Johansson; M Ingelman-Sundberg; F Sjöqvist
Journal:  Biochem Biophys Res Commun       Date:  1999-01-27       Impact factor: 3.575

View more
  33 in total

1.  Editors' pick 2010.

Authors:  Yoon K Loke; Albert Ferro; Lionel D Lewis; Adam F Cohen; Andrew Somogyi; James M Ritter
Journal:  Br J Clin Pharmacol       Date:  2011-01       Impact factor: 4.335

2.  Effect of CYP4F2, VKORC1, and CYP2C9 in Influencing Coumarin Dose: A Single-Patient Data Meta-Analysis in More Than 15,000 Individuals.

Authors:  Elisa Danese; Sara Raimondi; Martina Montagnana; Angela Tagetti; Taimour Langaee; Paola Borgiani; Cinzia Ciccacci; Antonio J Carcas; Alberto M Borobia; Hoi Y Tong; Cristina Dávila-Fajardo; Mariana Rodrigues Botton; Stephane Bourgeois; Panos Deloukas; Michael D Caldwell; Jim K Burmester; Richard L Berg; Larisa H Cavallari; Katarzyna Drozda; Min Huang; Li-Zi Zhao; Han-Jing Cen; Rocio Gonzalez-Conejero; Vanessa Roldan; Yusuke Nakamura; Taisei Mushiroda; Inna Y Gong; Richard B Kim; Keita Hirai; Kunihiko Itoh; Carlos Isaza; Leonardo Beltrán; Enrique Jiménez-Varo; Marisa Cañadas-Garre; Alice Giontella; Marianne K Kringen; Kari Bente Foss Haug; Hye Sun Gwak; Kyung Eun Lee; Pietro Minuz; Ming Ta Michael Lee; Steven A Lubitz; Stuart Scott; Cristina Mazzaccara; Lucia Sacchetti; Ece Genç; Mahmut Özer; Anil Pathare; Rajagopal Krishnamoorthy; Andras Paldi; Virginie Siguret; Marie-Anne Loriot; Vijay Kumar Kutala; Guilherme Suarez-Kurtz; Jamila Perini; Josh C Denny; Andrea H Ramirez; Balraj Mittal; Saurabh Singh Rathore; Hersh Sagreiya; Russ Altman; Mohamed Hossam A Shahin; Sherief I Khalifa; Nita A Limdi; Charles Rivers; Aditi Shendre; Chrisly Dillon; Ivet M Suriapranata; Hong-Hao Zhou; Sheng-Lan Tan; Vacis Tatarunas; Vaiva Lesauskaite; Yumao Zhang; Anke H Maitland-van der Zee; Talitha I Verhoef; Anthonius de Boer; Monica Taljaard; Carlo Federico Zambon; Vittorio Pengo; Jieying Eunice Zhang; Munir Pirmohamed; Julie A Johnson; Cristiano Fava
Journal:  Clin Pharmacol Ther       Date:  2019-02-17       Impact factor: 6.875

Review 3.  Personalized medicine: is it a pharmacogenetic mirage?

Authors:  Rashmi R Shah; Devron R Shah
Journal:  Br J Clin Pharmacol       Date:  2012-10       Impact factor: 4.335

Review 4.  Pharmacogenomics and personalized medicine: a review focused on their application in the Chinese population.

Authors:  Wen-ying Shu; Jia-li Li; Xue-ding Wang; Min Huang
Journal:  Acta Pharmacol Sin       Date:  2015-04-20       Impact factor: 6.150

5.  Impact of incorporating ABCB1 and CYP4F2 polymorphisms in a pharmacogenetics-guided warfarin dosing algorithm for the Brazilian population.

Authors:  Letícia C Tavares; Nubia E Duarte; Leiliane R Marcatto; Renata A G Soares; Jose E Krieger; Alexandre C Pereira; Paulo Caleb Junior Lima Santos
Journal:  Eur J Clin Pharmacol       Date:  2018-07-26       Impact factor: 2.953

6.  Influence of genetic polymorphisms in cytochrome P450 oxidoreductase on the variability in stable warfarin maintenance dose in Han Chinese.

Authors:  Wu-Tao Zeng; Qing Xu; Cheng-Hsun Li; Wei-Yan Chen; Xiu-Ting Sun; Xiang Wang; Yi-Ying Yang; Hui Shi; Zhi-Sheng Yang
Journal:  Eur J Clin Pharmacol       Date:  2016-08-04       Impact factor: 2.953

7.  Race-Specific Influence of CYP4F2 on Dose and Risk of Hemorrhage Among Warfarin Users.

Authors:  Aditi Shendre; Todd M Brown; Nianjun Liu; Charles E Hill; T Mark Beasley; Deborah A Nickerson; Nita A Limdi
Journal:  Pharmacotherapy       Date:  2016-03-14       Impact factor: 4.705

Review 8.  PharmGKB summary: very important pharmacogene information for CYP4F2.

Authors:  Maria L Alvarellos; Katrin Sangkuhl; Roxana Daneshjou; Michelle Whirl-Carrillo; Russ B Altman; Teri E Klein
Journal:  Pharmacogenet Genomics       Date:  2015-01       Impact factor: 2.089

9.  Impact of CYP2C9*3, VKORC1-1639, CYP4F2rs2108622 genetic polymorphism and clinical factors on warfarin maintenance dose in Han-Chinese patients.

Authors:  Ruijuan Liang; Lei Li; Cuilan Li; Yuanfeng Gao; Wenling Liu; Dayi Hu; Yihong Sun
Journal:  J Thromb Thrombolysis       Date:  2012-07       Impact factor: 2.300

10.  Influence of warfarin dose-associated genotypes on the risk of hemorrhagic complications in Chinese patients on warfarin.

Authors:  Cong Ma; Yuxiao Zhang; Qiang Xu; Jie Yang; Yan Zhang; Lei Gao; Bin Xu; Hongjuan Wang; Yang Li; Caiyi Lu; Tong Yin
Journal:  Int J Hematol       Date:  2012-10-27       Impact factor: 2.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.